CinDome Pharma

CinDome, a portfolio company of CinRx, is dedicated to providing safe, effective, and tolerable treatment options for millions of patients with chronic gastroparesis. In the United States, nearly 16 million adult patients suffer from gastroparesis symptoms, and a safe and effective chronic treatment remains a significant unmet need. CinDome's deudomperidone (CIN-102), an engineered formulation of the well-known D2/D3 antagonist domperidone, is a first-line treatment for gastroparesis globally but has yet to be approved in the United States.